Hidradenitis Suppurativa Treatment Market size is valued at USD 721.9 million in 2021 and is expected to grow at a prominent growth rate 4.50% during the forecast period 2022 to 2028. The global market provides a detailed overview of the global Hidradenitis Suppurativa Treatment market, and that can be segmented by Clinical Stage, by Drug Type, by Distribution Channel. By Clinical Stage, the global Hidradenitis Suppurativa Treatment market has been segmented into Hurley Stage 1, Hurley Stage 2, Hurley Stage 3. The hurley stage 1 Suppurativa Treatment segment is likely to be the largest and fastest-growing segment in terms of type. Based on Drug type, the global Hidradenitis Suppurativa Treatment market is segmented into Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Pain medications, Others. Among these, the biologics segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on distribution channel, the global Hidradenitis Suppurativa Treatment market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. The Hospital Pharmacies segment accounts for the largest share in 2021. Retail segment is the second-largest share during the forecast period 2022-2028.
In Feb 2019, InflaRx N.V., which is recognized for creating novel therapies to treat inflammatory diseases, recently released new clinical results including the use of IFX-1 in patients with moderate to severe Hidradenitis Suppurativa.
In March 2022, MoonLake began testing nanobody, sonelokimab in a Phase II clinical trial to treat moderate-to-severe hidradenitis suppurativa (HS). By blocking the IL-17A/A, IL-17A/F, and IL-17F/F dimers that induce inflammation in the body, sonelokimab may be able to cure inflammatory conditions.